Imagen de Portada

Challenging the Detection of Comedication Interactions Related to Immune‐Related Adverse Events Using Spontaneous Reporting Systems

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Yuki Nakano
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Response to Letters Regarding “Comedications Associated with Immune‐Related Adverse Events from Immune‐Checkpoint Inhibitors”
por: Léonard Laurent, et al.
Publicado: (2025)

A Consideration of Exploratory Approaches to Comedications Associated With Immune‐Related Adverse Events during Immune Checkpoint Inhibitor Therapy
por: Yoshihiro Noguchi, et al.
Publicado: (2025)

FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception
por: Emanuel Raschi, et al.
Publicado: (2025)

Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation
por: Emanuel Raschi, et al.
Publicado: (2025)

Risk of Malignancies and Major Adverse Cardiovascular Events Related to JAK Inhibitors in Rheumatoid Arthritis: A Meta‐Analysis
por: Hongmei Duan, et al.
Publicado: (2025)

Drug‐Induced Acute Pancreatitis: A Real‐World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
por: Dongxuan Li, et al.
Publicado: (2024)

Predictive Modeling of Drug‐Related Adverse Events with Real‐World Data: A Case Study of Linezolid Hematologic Outcomes
por: Anu Patel, et al.
Publicado: (2024)

Identifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
por: Elpida Kontsioti, et al.
Publicado: (2024)

Major Adverse Cardiac Events with Ondansetron: A Systematic Review
por: Michael Cristian Garcia, et al.
Publicado: (2025)

Drug‐Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources
por: Anna Maria Wermund, et al.
Publicado: (2025)

Algorithmic Identification of Treatment‐Emergent Adverse Events From Clinical Notes Using Large Language Models: A Pilot Study in Inflammatory Bowel Disease
por: Anna L. Silverman, et al.
Publicado: (2024)

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study
por: Samia Shabnaz, et al.
Publicado: (2026)

The Persistent Ambiguity of Adverse Drug Reactions
por: Edward M. Sellers, et al.
Publicado: (2025)

Discovering Severe Adverse Reactions From Pharmacokinetic Drug–Drug Interactions Through Literature Analysis and Electronic Health Record Verification
por: Eugene Jeong, et al.
Publicado: (2024)

Characterizing Alzheimer’s Disease and Related Dementia in a Hypertension Population Within the State of Florida Using Electronic Health Record–Based Data
por: Eissa A. Jafari, et al.
Publicado: (2025)

The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines
por: Janine Scholefield, et al.
Publicado: (2026)

Using Machine Learning to Individualize Treatment Effect Estimation: Challenges and Opportunities
por: Alicia Curth, et al.
Publicado: (2024)

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Studies Related to Vincristine‐Induced Peripheral Neuropathy in Chinese Pediatric ALL Patients
por: Yawen Yuan, et al.
Publicado: (2024)

Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL
por: Candice Jamois, et al.
Publicado: (2025)

Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment‐Naive Patients Compared With Zoledronate
por: Ko‐Hsiu Lu, et al.
Publicado: (2026)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data
por: Natalia Sauer, et al.
Publicado: (2026)

Aging‐Related CYP3A Functional Changes in Chinese Older Patients: New Findings from Model‐Based Assessment of Amlodipine
por: Jie En Valerie Sia, et al.
Publicado: (2024)

Transdermal Nicotine Patch Increases the Number and Function of Endothelial Progenitor Cells in Young Healthy Nonsmokers without Adverse Hemodynamic Effects
por: Yen‐Yu Liu, et al.
Publicado: (2024)

An Evaluation of the Drug Interaction Potential of Encorafenib in Combination With Binimetinib Using the Inje Cocktail in Patients With Cancer
por: Joseph Piscitelli, et al.
Publicado: (2025)

The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence‐Based Medicine
por: Charles Khouri, et al.
Publicado: (2025)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
por: Kunal S. Taskar, et al.
Publicado: (2025)

Uncovering Coenzyme Q10 ‐Related Genetic Determinants of Statin‐Associated Muscle Symptoms: Evidence from the UK Biobank and the All of Us Research Program
por: Da Hoon Lee, et al.
Publicado: (2026)

Summary Report of a Public Workshop: Case Studies of Multi‐Regional Clinical Trial Incorporating Concept of the ICH E17 Guideline
por: Nobuko Matsushima, et al.
Publicado: (2024)

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
por: Sejung Hwang, et al.
Publicado: (2024)

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
por: Yuki Ujihira, et al.
Publicado: (2025)

Drug Interactions Brewing
por: Matthijs W. van Hoogdalem, et al.
Publicado: (2025)

Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
por: Teng‐Li Lin, et al.
Publicado: (2026)

Machine Learning for Prediction of Drug Concentrations: Application and Challenges
por: Shuqi Huang, et al.
Publicado: (2025)

Concomitant Use of Oral Anticoagulants With Oral Dipeptidyl Peptidase‐4 Inhibitors and Serious Bleeding Events
por: Thanh Phuong Pham Nguyen, et al.
Publicado: (2024)

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
por: Alan Faraj, et al.
Publicado: (2024)

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges
por: D. Max Smith, et al.
Publicado: (2025)

Navigating the Challenges of Cyclosporine as an Alternative to Rifampicin as an OATP1B Index Inhibitor
por: Manthena V. S. Varma, et al.
Publicado: (2025)

Insights into Clinical Trials for Drugs Targeting MASLD: Progress, Challenges, and Future Directions
por: Yu Wu, et al.
Publicado: (2025)

Association of Pregabalin vs. Duloxetine with Cardiovascular Events: A Retrospective Cohort Study Among US Veterans With Chronic Musculoskeletal Pain
por: Sachalee Campbell, et al.
Publicado: (2026)

Population Time‐to‐Event Modeling of Pregnancy Loss Risk Following Frozen Embryo Transfer: A Real‐World Study in Chinese Women
por: Wen Yao Mak, et al.
Publicado: (2025)